The current standard therapy for the treatment of chronic hepatitis C virus (HCV) is the combination of peginterferon and ribavirin, although many patients fail to clear the virus and their retreatment options are still unsatisfactory. Thymosin alpha1 (Talpha1) is an immunomodulating agent that has been proposed as complementary therapy for chronic HCV, especially in the setting of difficult-to-treat patients. The aim of this study was to evaluate, in patients nonresponsive to previous Peg-based therapy, the effect of standard antiviral therapy with or without Talpha1 on peripheral lymphocyte subsets. Twenty-four patients, 12 receiving Talpha1 and 12 standard therapy, were enrolled. Peripheral subpopulations were analyzed by flow cytometry. Although the addition of Talpha1 did not seem to significantly modify the T-lymphocyte subpopulations, as comparable behaviors were observed in the CD4 and CD8 longitudinal evaluation, Talpha1 produced an earlier increase of natural killer cells. An accurate selection of HCV patients who can benefit from immunomodulation is needed
Grandini E, Cannoletta F, Scuteri A, Fortini C, Loggi E, Cursaro C, et al. (2010). Immunological modifications during treatment with thymosin alpha 1 plus antiviral therapy in chronic hepatitis C. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1194, 147-152 [10.1111/j.1749-6632.2010.05461.x].
Immunological modifications during treatment with thymosin alpha 1 plus antiviral therapy in chronic hepatitis C.
GRANDINI, ELENA;CANNOLETTA, FRANCESCA;SCUTERI, ALESSANDRA;FORTINI, CINZIA;LOGGI, ELISABETTA;RIILI, ANNA;DI DONATO, ROBERTO;GRAMENZI, ANNAGIULIA;BERNARDI, MAURO;ANDREONE, PIETRO
2010
Abstract
The current standard therapy for the treatment of chronic hepatitis C virus (HCV) is the combination of peginterferon and ribavirin, although many patients fail to clear the virus and their retreatment options are still unsatisfactory. Thymosin alpha1 (Talpha1) is an immunomodulating agent that has been proposed as complementary therapy for chronic HCV, especially in the setting of difficult-to-treat patients. The aim of this study was to evaluate, in patients nonresponsive to previous Peg-based therapy, the effect of standard antiviral therapy with or without Talpha1 on peripheral lymphocyte subsets. Twenty-four patients, 12 receiving Talpha1 and 12 standard therapy, were enrolled. Peripheral subpopulations were analyzed by flow cytometry. Although the addition of Talpha1 did not seem to significantly modify the T-lymphocyte subpopulations, as comparable behaviors were observed in the CD4 and CD8 longitudinal evaluation, Talpha1 produced an earlier increase of natural killer cells. An accurate selection of HCV patients who can benefit from immunomodulation is neededI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
